KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Inventory: 2018-2025

Historic Inventory for Twist Bioscience (TWST) over the last 7 years, with Sep 2025 value amounting to $28.3 million.

  • Twist Bioscience's Inventory rose 17.57% to $28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.3 million, marking a year-over-year increase of 17.57%. This contributed to the annual value of $28.3 million for FY2025, which is 17.57% up from last year.
  • As of Q3 2025, Twist Bioscience's Inventory stood at $28.3 million, which was up 9.14% from $25.9 million recorded in Q2 2025.
  • Over the past 5 years, Twist Bioscience's Inventory peaked at $44.6 million during Q4 2022, and registered a low of $15.8 million during Q1 2021.
  • Moreover, its 3-year median value for Inventory was $28.5 million (2024), whereas its average is $29.2 million.
  • Its Inventory has fluctuated over the past 5 years, first surged by 200.09% in 2021, then tumbled by 31.33% in 2025.
  • Twist Bioscience's Inventory (Quarterly) stood at $40.2 million in 2021, then rose by 10.83% to $44.6 million in 2022, then tumbled by 30.80% to $30.9 million in 2023, then dropped by 23.80% to $23.5 million in 2024, then rose by 17.57% to $28.3 million in 2025.
  • Its last three reported values are $28.3 million in Q3 2025, $25.9 million for Q2 2025, and $20.9 million during Q1 2025.